Clinical Trial Update: Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

The completed Phase 2 trial evaluated the combination of doxorubicin and interleukin-2 in patients with unresectable liver cancer. The update reports safety and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Adriamycin (doxorubicin)
• Proleukin (aldesleukin)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED